Year |
Citation |
Score |
2022 |
Prout A, Rustandi RR, Tubbs C, Winters MA, McKenna P, Vlasak J. Functional profiling of Covid 19 vaccine candidate by flow virometry. Vaccine. PMID 35985887 DOI: 10.1016/j.vaccine.2022.08.006 |
0.428 |
|
2010 |
Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Tynebor RM, Tucker TJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 54: 4812-24. PMID 20805392 DOI: 10.1128/Aac.00829-10 |
0.372 |
|
2010 |
Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, Ingallinella P, McKenna P, Citron M, Ottinger E, Hepler RW, Hrin R, Nahas D, Wu C, Montefiori D, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proceedings of the National Academy of Sciences of the United States of America. 107: 10655-60. PMID 20483992 DOI: 10.1073/Pnas.1004261107 |
0.664 |
|
2010 |
Wang YJ, McKenna PM, Hrin R, Felock P, Lu M, Jones KG, Coburn CA, Grobler JA, Hazuda DJ, Miller MD, Lai MT. Assessment of the susceptibility of mutant HIV-1 to antiviral agents. Journal of Virological Methods. 165: 230-7. PMID 20153375 DOI: 10.1016/j.jviromet.2010.02.002 |
0.378 |
|
2009 |
Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrobial Agents and Chemotherapy. 53: 2424-31. PMID 19289522 DOI: 10.1128/Aac.01559-08 |
0.455 |
|
2007 |
McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. The Journal of Infectious Diseases. 195: 980-8. PMID 17330788 DOI: 10.1086/512243 |
0.731 |
|
2006 |
Plesa G, McKenna PM, Schnell MJ, Eisenlohr LC. Immunogenicity of cytopathic and noncytopathic viral vectors. Journal of Virology. 80: 6259-66. PMID 16775313 DOI: 10.1128/Jvi.00084-06 |
0.593 |
|
2006 |
McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology. 344: 363-77. PMID 16226782 DOI: 10.1016/J.Virol.2005.09.004 |
0.691 |
|
2005 |
Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology. 331: 82-93. PMID 15582655 DOI: 10.1016/J.Virol.2004.10.018 |
0.727 |
|
2004 |
McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, Marx PA, Pomerantz RJ, Lackner A, Schnell MJ. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. Journal of Virology. 78: 13455-9. PMID 15564456 DOI: 10.1128/Jvi.78.24.13455-13459.2004 |
0.721 |
|
2003 |
McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Current Hiv Research. 1: 229-37. PMID 15043205 DOI: 10.2174/1570162033485320 |
0.737 |
|
2003 |
McKenna PM, Pomerantz RJ, Dietzschold B, McGettigan JP, Schnell MJ. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. Journal of Virology. 77: 12782-94. PMID 14610200 DOI: 10.1128/Jvi.77.23.12782-12794.2003 |
0.68 |
|
2003 |
McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, Schnell MJ. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. Journal of Virology. 77: 10889-99. PMID 14512539 DOI: 10.1128/Jvi.77.20.10889-10899.2003 |
0.726 |
|
2003 |
McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. Journal of Virology. 77: 237-44. PMID 12477829 DOI: 10.1128/Jvi.77.1.237-244.2003 |
0.727 |
|
2002 |
McGettigan JP, McKenna PM, Schnell MJ. HIV-1 vaccines: the search continues. Clinics in Laboratory Medicine. 22: 799-820, viii. PMID 12244598 DOI: 10.1016/S0272-2712(02)00004-5 |
0.679 |
|
1998 |
Robert-Guroff M, Kaur H, Patterson LJ, Leno M, Conley AJ, McKenna PM, Markham PD, Richardson E, Aldrich K, Arora K, Murty L, Carter L, Zolla- Pazner S, Sinangil F. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus Journal of Virology. 72: 10275-10280. PMID 9811775 DOI: 10.1128/Jvi.72.12.10275-10280.1998 |
0.65 |
|
1998 |
Geffin RB, Scott GB, Melenwick M, Hutto C, Lai S, Boots LJ, McKenna PM, Kessler JA, Conley AJ. Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1. Aids Research and Human Retroviruses. 14: 579-90. PMID 9591712 |
0.395 |
|
1997 |
Boots LJ, McKenna PM, Arnold BA, Keller PM, Gorny MK, Zolla-Pazner S, Robinson JE, Conley AJ. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. Aids Research and Human Retroviruses. 13: 1549-59. PMID 9430247 DOI: 10.1089/Aid.1997.13.1549 |
0.353 |
|
1997 |
Kessler JA, McKenna PM, Emini EA, Chan CP, Patel MD, Gupta SK, Mark GE, Barbas CF, Burton DR, Conley AJ. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. Aids Research and Human Retroviruses. 13: 575-82. PMID 9135875 |
0.431 |
|
1996 |
Conley AJ, Kessler JA, Boots LJ, McKenna PM, Schleif WA, Emini EA, Mark GE, Katinger H, Cobb EK, Lunceford SM, Rouse SR, Murthy KK. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. Journal of Virology. 70: 6751-8. PMID 8794312 |
0.379 |
|
1994 |
Nguyen MH, Schinazi RF, Shi C, Goudgaon NM, McKenna PM, Mellors JW. Resistance of human immunodeficiency virus type 1 to acyclic 6- phenylselenenyl- and 6-phenylthiopyrimidines Antimicrobial Agents and Chemotherapy. 38: 2409-2414. PMID 7840579 |
0.348 |
|
Show low-probability matches. |